chemotherapy-Shandong Provincial Hospital-lymphoma (Non-Hodgkin)

"chemotherapy-Shandong Provincial Hospital-lymphoma (Non-Hodgkin)" refers to the standard-of-care chemotherapy regimens utilized as a comparator or combination partner in a Phase 4 clinical trial (NCT04014036) conducted by **Shandong Provincial Hospital**. This trial evaluates the efficacy and safety of the PD-1 inhibitor sintilimab in patients with relapsed or refractory **Non-Hodgkin Lymphoma (NHL)**. The chemotherapy component is not a single agent but a selection of established multi-drug regimens, including **GDP** (gemcitabine, cisplatin, dexamethasone), **GemOx** (gemcitabine, oxaliplatin), **DA-EPOCH** (etoposide, prednisone, vincristine, cyclophosphamide, epirubicin), **ICE** (ifosfamide, cisplatin, etoposide), **DICE** (dexamethasone, ifosfamide, cisplatin, etoposide), **high-dose methotrexate (MTX)**, or **Hyper-CVAD** (cyclophosphamide, vincristine, epirubicin, dexamethasone, methotrexate, cytarabine). Additionally, **rituximab** is administered to patients in this arm unless they relapsed within 12 months of prior rituximab therapy. These agents exert anti-tumor effects through diverse cytotoxic mechanisms, including DNA cross-linking, inhibition of topoisomerase II, disruption of microtubule assembly, and interference with DNA synthesis and metabolic pathways.

Other names

GDPGemOxDA-EPOCHICEDICEHyper-CVADMTX